Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarextumab + EP in ES-SCLC (PINNACLE)
NCT01859741Phase 2Terminated
- Sponsor
- OncoMed Pharmaceuticals
- Start
- Jan 2012
- Primary completion
- Apr 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tarextumab in small cell lung cancer (SCLC), sponsored by OncoMed Pharmaceuticals. Started Jan 2012; status: terminated.
02
Drugs
tarextumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT01859741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01859741.